The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%

Japanese Journal of Clinical Oncology

Volumn 38, Issue 12, 2008, Pages 844-848

  Ishidoya, Shigeto ^a   Ito, Akihiro ^a   Orikasa, Kazuhiko ^a   Kawamura, Sadafumi ^b   Tochigi, Tatsuo ^b   Kuwahara, Masaaki ^b   Yamanobe, Takuya ^c   Tomita, Yoshihiko ^c   Masumori, Naoya ^d   Tsukamoto, Taiji ^d   Shibuya, Daisuke ^e   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Miyagi Cancer Center ^*  (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

free PSA; Prostate cancer; PSA; Screening

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; JAPANESE; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; POPULATION RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; VOLUNTEER;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 57349175609     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn107     Document Type: Article

References (13)

1. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
2. Vessella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, et al. Probability of prostate cancer detection based on a multicenter study using the AxSYM free PSA and total PSA assays. Urology 2000;55:909-14.
3. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:517-22.
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542-7.
5. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4.0 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model. Urology 1999;54:220-4.
6. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
7. Pelzer AE, Volgger H, Bektic J, Berger AP, Rehder P, Bartsch G, et al. The effect of percentage free prostate-specific antigen (PSA) level on prostate cancer detection rate in a screening population with low PSA levels. BJU Int 2005;96:995-8.
8. Schroder FH. Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges. Eur Urol 2001;39:49-53.
9. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA, Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/mL: Relation to biopsy strategy. J Urol 2001;165:757-60.
10. Kobayashi T, Kamoto T, Nishizawa K, Mitsumori K, Ogura K, Ide Y. Prostate-specific antigen (PSA) complexed to α1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL. BJU Int 2005;95:761-5.
11. Bangma CH, Kranse I, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate cancer. J Urol 1997;157:544-7.
12. Pepe P, Panella P, Pietropaolo F, Pennisi M, Allegro R, Aragona F. Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSA ≤10 ng/ml? Urol Int 2006;76:232-5.
13. Kuwahara M, Tochigi T, Kawamura S, Ogata Y, Xu N, Wang H, et al. Mass screening for prostate cancer: A comparative study in Natori, Japan and Changchun, China. Urology 2003;314:137-41.